Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.

about

Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.

P2860

Q48190879-3672065A-6FA3-4FA3-9EA9-2AB927A22094

P2860

Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.

Item

http://www.wikidata.org/entity/Q38725261

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Novel splice-switching oligonu ...... lity to PARP inhibitor action.

@en

type

Item

label

Novel splice-switching oligonu ...... lity to PARP inhibitor action.

@en

prefLabel

Novel splice-switching oligonu ...... lity to PARP inhibitor action.

@en

P1476

Novel splice-switching oligonu ...... ility to PARP inhibitor action

@en

P2093

Diana Baralle

http://www.w3.org/2001/XMLSchema#string

Flávia Leme de Calais

http://www.w3.org/2001/XMLSchema#string

Lindsay D Smith

http://www.w3.org/2001/XMLSchema#string

Michela Raponi

http://www.w3.org/2001/XMLSchema#string

P2860

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Megabase chromatin domains involved in DNA double-strand breaks in vivo

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

SF3B1 mutations constitute a novel therapeutic target in breast cancer.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage

Association of BRCA1 with Rad51 in mitotic and meiotic cells

Brca1 controls homology-directed DNA repair

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon.

P304

1564-1570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.30574

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

Emanuele Buratti

Jeremy P Blaydes

Massimiliano Mellone

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27997688

http://www.w3.org/2001/XMLSchema#string

Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.

about

P2860

P2860

Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698